Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1162-1176. doi: 10.1016/S2468-1253(24)00245-0.
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterised by symptoms of abdominal pain, occurring at least 1 day per week, and a change in stool frequency or form. Individuals with IBS are usually subtyped according to their predominant bowel habit, which is used to direct symptom-based treatment. However, this approach is probably an oversimplification of a complex and multidimensional condition, and other factors, such as psychological health, are known to influence symptom severity and prognosis. We have previously used latent class analysis, a method of mathematical modelling, to show that people with IBS can be classified into seven unique clusters based on a combination of gastrointestinal symptoms, abdominal pain, extraintestinal symptoms, and psychological comorbidity. The clusters can be used to predict the prognosis of IBS (eg, symptom severity), health-care use (eg, consultation behaviour, prescribing, and costs), and impact (eg, quality of life, work and productivity, activities of daily living, and income). These clusters could also be used to increase the personalisation of IBS treatment that better recognises the heterogenous nature of the condition. We present new data providing additional validation of our seven-cluster model and conduct a comprehensive evidence-based review of IBS management. Based on this evidence, we propose a framework of first-line and second-line treatments according to IBS cluster. Finally, we discuss what further research is needed to implement this approach in clinical practice, including the need for randomised trials comparing cluster-based treatment with conventional treatment according to stool subtype.
肠易激综合征(IBS)是一种常见的肠脑相互作用障碍,其特征为腹痛症状,每周至少发作 1 天,以及粪便频率或形态的改变。IBS 患者通常根据其主要的肠道习惯进行亚型分类,这用于指导基于症状的治疗。然而,这种方法可能过于简化了一种复杂的多维疾病,并且其他因素,如心理健康,已知会影响症状严重程度和预后。我们之前使用潜在类别分析(一种数学建模方法)表明,IBS 患者可以根据胃肠道症状、腹痛、肠外症状和心理共病的组合分为七个独特的聚类。这些聚类可用于预测 IBS 的预后(例如,症状严重程度)、医疗保健使用(例如,咨询行为、处方和费用)和影响(例如,生活质量、工作和生产力、日常生活活动和收入)。这些聚类还可以用于增加 IBS 治疗的个性化,更好地认识到该疾病的异质性。我们提出了新的数据,提供了对我们的七聚类模型的额外验证,并对 IBS 管理进行了全面的基于证据的综述。基于这些证据,我们根据 IBS 聚类提出了一线和二线治疗的框架。最后,我们讨论了在临床实践中实施这种方法需要进一步研究什么,包括需要比较基于聚类的治疗与根据粪便亚型的常规治疗的随机试验。
Lancet Gastroenterol Hepatol. 2024-12
Autism Adulthood. 2025-5-28
Autism Adulthood. 2025-5-28
Cochrane Database Syst Rev. 2025-6-16
Ont Health Technol Assess Ser. 2025-5-1
Cochrane Database Syst Rev. 2025-6-9
Cochrane Database Syst Rev. 2024-6-19
Cochrane Database Syst Rev. 2025-6-20
Neuropsychiatr Dis Treat. 2025-8-25
Nat Rev Gastroenterol Hepatol. 2025-4-25
Life (Basel). 2025-2-11